Contact
searchSearch
HMP Global
Login
News
Post-Treatment Plasma ctDNA Accurately Identifies Recurrence in Muscle-Invasive Bladder Cancer
02/09/2026
Stephanie Holland
According to results from a retrospective analysis, plasma ctDNA demonstrated strong potential as a biomarker for early detection of metastatic recurrence in patients with muscle-invasive bladder cancer treated with trimodality therapy.
According to results from a retrospective analysis, plasma ctDNA demonstrated strong potential as a biomarker for early detection of metastatic recurrence in patients with muscle-invasive bladder cancer treated with trimodality therapy.
According to results from a...
02/09/2026
Oncology
News
Selective Use of Stereotactic Ablative Radiotherapy Enables Durable Disease Control in Oligoprogressive Metastatic Renal Cell Carcinoma
02/06/2026
Stephanie Holland
Stereotactic ablative radiotherapy provides durable local control and delays systemic therapy escalation in selected patients with oligoprogressive metastatic renal cell carcinoma receiving systemic therapy.
Stereotactic ablative radiotherapy provides durable local control and delays systemic therapy escalation in selected patients with oligoprogressive metastatic renal cell carcinoma receiving systemic therapy.
Stereotactic ablative...
02/06/2026
Oncology
Mustafa Basree, DO, University of Wisconsin
Videos
Personalized Dosimetry Guides 177Lu-PSMA-617 Therapy in Prostate Cancer
02/06/2026
Mustafa Basree, DO
Mustafa Basree, DO, discusses institutional experience using voxel-level, patient-specific dosimetry to personalize 177Lu-PSMA-617 dosing in patients with metastatic castration-resistant prostate cancer.
Mustafa Basree, DO, discusses institutional experience using voxel-level, patient-specific dosimetry to personalize 177Lu-PSMA-617 dosing in patients with metastatic castration-resistant prostate cancer.
Mustafa Basree, DO, discusses...
02/06/2026
Radiopharmaceutical Education Institute
Lucian Zhao, MD
Videos
Stereotactic Ablative Radiotherapy Delays Systemic Therapy Escalation in Oligoprogressive Renal Cell Carcinoma
02/06/2026
Lucian Zhao, MD
Lucian Zhao, MD, discusses outcomes from a large retrospective analysis evaluating SAbR in patients with oligoprogressive metastatic renal cell carcinoma undergoing systemic therapy.
Lucian Zhao, MD, discusses outcomes from a large retrospective analysis evaluating SAbR in patients with oligoprogressive metastatic renal cell carcinoma undergoing systemic therapy.
Lucian Zhao, MD, discusses...
02/06/2026
Oncology
Manisha Palta, MD, Duke University Cancer Center
Videos
An Argument for Radiation in the Neoadjuvant Setting for Pancreatic Cancer
03/23/2023
At the 2023 ACRO Radiation Oncology Summit, Manisha Palta, MD, discussed the role of radiation therapy in the neoadjuvant setting for patients with pancreatic cancer.
At the 2023 ACRO Radiation Oncology Summit, Manisha Palta, MD, discussed the role of radiation therapy in the neoadjuvant setting for patients with pancreatic cancer.
At the 2023 ACRO Radiation...
03/23/2023
Oncology
Gerard Morton, MD, Odette Cancer Center at Sunnybrook Research Institute
Videos
Methods of Radiation Dose Intensification for High-Risk Prostate Cancer
03/21/2023
At the 2023 ACRO Radiation Oncology Summit, Gerard Morton, MD, discusses the different methods of radiation dose intensification for patients with high-risk prostate cancer.
At the 2023 ACRO Radiation Oncology Summit, Gerard Morton, MD, discusses the different methods of radiation dose intensification for patients with high-risk prostate cancer.
At the 2023 ACRO Radiation...
03/21/2023
Oncology
Mylin Torres, MD, Winship Cancer Institute
Videos
Five-Fraction Radiation Regimens for Early-Stage Breast Cancer
03/20/2023
At the 2023 ACRO Radiation Oncology Summit, Mylin Torres, MD, gave a presentation exploring the option of 5-fraction radiation regimens for patients with early-stage breast cancer.
At the 2023 ACRO Radiation Oncology Summit, Mylin Torres, MD, gave a presentation exploring the option of 5-fraction radiation regimens for patients with early-stage breast cancer.
At the 2023 ACRO Radiation...
03/20/2023
Oncology
Maria Werner-Wasik, MD, Sidney Kimmel Cancer Center
Videos
Chemoimmunotherapy and the Changing Landscape of Preoperative Treatment for Stage III Non-Small Cell Lung Cancer
03/20/2023
At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.
At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.
At the 2023 ACRO Radiation...
03/20/2023
Oncology
Maria Werner-Wasik, MD, Sidney Kimmel Cancer Center
Videos
How Preoperative Chemoimmunotherapy May Change Management of Patients With Stage III Non-Small Cell Lung Cancer
03/20/2023
At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.
At the 2023 ACRO Radiation Oncology Summit, Maria Werner-Wasik, MD, discussed preoperative treatment options for stage III non-small cell lung cancer.
At the 2023 ACRO Radiation...
03/20/2023
Oncology
Quiz
Quiz: Does Metoformin, CCRT Combo Improve OS in NSCLC?
03/30/2022
True or false: Results from a randomized clinical trial suggest that adding metformin to concurrent chemoradiation (CCRT) does not improve survival in patients with unresectable stage III non-small cell lung cancer.
True or false: Results from a randomized clinical trial suggest that adding metformin to concurrent chemoradiation (CCRT) does not improve survival in patients with unresectable stage III non-small cell lung cancer.
True or false: Results from a...
03/30/2022
Oncology
Adding Metformin to CCRT Does Not Improve Survival in NSCLC
03/23/2022
Although adding metformin to concurrent chemoradiation was well tolerated, it offered no survival benefit for patients with unresectable stage III NSCLC.
Although adding metformin to concurrent chemoradiation was well tolerated, it offered no survival benefit for patients with unresectable stage III NSCLC.
Although adding metformin to...
03/23/2022
Oncology
Quiz
Quiz: Does Nivolumab Impact Surgical Outcomes in Residual Disease?
03/16/2022
According to data presented at the ACRO conference, adjuvant nivolumab following surgery for patients with residual pathological disease results in a doubling of DFS.
According to data presented at the ACRO conference, adjuvant nivolumab following surgery for patients with residual pathological disease results in a doubling of DFS.
According to data presented at...
03/16/2022
Oncology
elderly screening patient
Quiz
Novel MS-VMAT Technique for Whole Lung Irradiation
03/15/2022
Alexis Hyams
At the 2022 ACRO Annual Meeting, experts revealed that a dosimetric advantage was observed with bone marrow sparing VMAT over the standard technique for whole lung irradiation.
At the 2022 ACRO Annual Meeting, experts revealed that a dosimetric advantage was observed with bone marrow sparing VMAT over the standard technique for whole lung irradiation.
At the 2022 ACRO Annual Meeting,...
03/15/2022
Oncology
Dr Chuong
Videos
Dr Chuong Highlights Ablative MR-Guided Radiation Therapy in Inoperable Pancreatic Cancer
10/04/2021
Michael Chuong, MD, Miami Cancer Institute, discusses a 5 day, minimally invasive, ablative MR-guided radiation therapy, proven to maintain a high quality of life in patients with inoperable pancreas cancer.
Michael Chuong, MD, Miami Cancer Institute, discusses a 5 day, minimally invasive, ablative MR-guided radiation therapy, proven to maintain a high quality of life in patients with inoperable pancreas cancer.
Michael Chuong, MD, Miami Cancer...
10/04/2021
Oncology
Quiz
Quiz: Dose Escalation in Esophageal Cancer
08/15/2021
True or false: According to experts who presented at the ACRO Annual Conference, dose escalation is achievable for patients with esophageal cancer.
True or false: According to experts who presented at the ACRO Annual Conference, dose escalation is achievable for patients with esophageal cancer.
True or false: According to...
08/15/2021
Oncology
Interview
CXB After EBRT/EBCRT in Patients With Rectal Cancer Not Eligible for Surgery
01/28/2020
Arthur Sun Myint, FRCP, FFRCS, FRCR, FICS, discusses the significance of a trial on the role of CXB after EBRT or EBCRT in certain patients with rectal cancer.
Arthur Sun Myint, FRCP, FFRCS, FRCR, FICS, discusses the significance of a trial on the role of CXB after EBRT or EBCRT in certain patients with rectal cancer.
Arthur Sun Myint, FRCP, FFRCS,...
01/28/2020
Oncology

At the Radiation Oncology Summit: ACRO, attendees can learn about the latest research updates in radiation oncology and network with like-minded colleagues in the radiology space.

What Your Colleagues are Reading

FDA Approval
FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer
05/01/2024

Stephanie Holland 

Stephanie Holland 
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Based on results from the phase...
05/01/2024
Oncology
Ryan Moy, MD
Conference Coverage
PD-1 Inhibitors for First-Line Treatment of Patients With Gastroesophageal Cancers
05/18/2024
At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Ryan Moy, MD, PhD, discussed first-line use of PD-1 inhibitors for the treatment of patients with gastroesophageal cancers.
At Great Debates and Updates in Gastrointestinal Malignancies in New York, New York, Ryan Moy, MD, PhD, discussed first-line use of PD-1 inhibitors for the treatment of patients with gastroesophageal cancers.
At Great Debates and Updates in...
05/18/2024
Oncology
Areej El-Jawahri, MD, Massachusetts General Hospital
Conference Coverage
Palliative Care vs Standard of Care in Discussion of End-of-Life Care Preferences for Patients With AML and MDS
06/01/2024

Featuring Areej El-Jawahri, MD

Featuring Areej El-Jawahri, MD ...
Areej El-Jawahri MD, discusses trial results that showed palliative care significantly improved the rates of discussion and documentation of end-of-life care preferences, reduced hospitalization, and improved quality of life for patients with...
Areej El-Jawahri MD, discusses trial results that showed palliative care significantly improved the rates of discussion and documentation of end-of-life care preferences, reduced hospitalization, and improved quality of life for patients with...
Areej El-Jawahri MD, discusses...
06/01/2024
Oncology
Conference Coverage
Tisotumab Vedotin Showed Promising Clinical Activity Among Heavily Pretreated Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
06/11/2024

Stephanie Holland 

Stephanie Holland 
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results from the phase 2 innovaTV 207 trial, tisotumab vedotin showed promising clinical activity among patients with heavily pretreated recurrent or metastatic head and neck squamous cell carcinoma.
According to updated results...
06/11/2024
Oncology
Reshma Mahtani, DO; Terry Mamounas, MD; Jane Meisel, MD
Videos
Pertuzumab Plus Trastuzumab for Early-Stage HER2-Positive Breast Cancer
06/20/2024
In this video, a panel of experts highlight 8-year updated results from the APHINITY trial and reflect on the progress that has been made in the setting of HER2-positive breast cancer.
In this video, a panel of experts highlight 8-year updated results from the APHINITY trial and reflect on the progress that has been made in the setting of HER2-positive breast cancer.
In this video, a panel of...
06/20/2024
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use